Cargando…

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Detalles Bibliográficos
Autores principales:	Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne M., Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314733/ https://www.ncbi.nlm.nih.gov/pubmed/34260834 http://dx.doi.org/10.1056/NEJMc2108829

Ejemplares similares

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
por: Mahrokhian, Shant H., et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
por: Sadoff, Jerald, et al.
Publicado: (2021)

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
por: Tostanoski, Lisa H., et al.
Publicado: (2022)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant
por: Liu, Jinyan, et al.
Publicado: (2022)

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
por: Roozendaal, Ramon, et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
por: Liu, Jinyan, et al.
Publicado: (2022)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

A plain language summary of how well the single-dose Janssen vaccine works and how safe it is
por: Sadoff, J, et al.
Publicado: (2021)

A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
por: Nkolola, Joseph P., et al.
Publicado: (2022)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
por: McMahan, Katherine, et al.
Publicado: (2020)

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
por: He, Xuan, et al.
Publicado: (2022)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

A genetically engineered, stem-cell-derived cellular vaccine
por: Cooper, Amanda, et al.
Publicado: (2022)

Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
por: Ong-Lim, Anna Lisa, et al.
Publicado: (2022)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
por: Gebre, Makda S., et al.
Publicado: (2021)

Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
por: He, Xuan, et al.
Publicado: (2021)

Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
por: Chang, Aiquan, et al.
Publicado: (2022)

mRNA Vaccines Induce Rapid Antibody Responses in Mice
por: Gebre, Makda S., et al.
Publicado: (2021)

mRNA vaccines induce rapid antibody responses in mice
por: Gebre, Makda S., et al.
Publicado: (2022)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
por: Chandrashekar, Abishek, et al.
Publicado: (2021)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
por: Yu, Jingyou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vs4v1fsdhb83gf46kjbhp93jah